Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France

Guillon, P.; Harmand, Sarah; Ansolabehere, X.

doi:10.5414/cp203427

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from our study are in line with previous publications that patients on paliperidone palmitate have a higher treatment continuation than patients on risperidone microspheres [ 19 , 20 , 24 ]. We also found that PP3M patients have a significantly lower treatment discontinuation than PP1M patients (19.2% vs 37.1%, p < 0.001) in the one-year follow up.…”

Section: Discussionsupporting

confidence: 92%

“…The continuation rates in this study were comparable to other studies with similar study design. A retrospective observational study using IQVIA French LRx showed non-discontinuation (for five months or longer) rate of paliperidone palmitate and risperidone microspheres was 64.5% and 35.4%, respectively [ 20 ]. In our study, the respective continuation rates were 62.5% and 32.8% by the fifth month.…”

Section: Discussionmentioning

confidence: 99%

“…However, difference in terms of treatment continuation between LATs was not very well studied. Recent studies have shown paliperidone palmitate can result in similar or better treatment continuation as compared to aripiprazole [ 17 ] and other LAT such as risperidone microspheres [ 18 – 20 ]. However, factors associated with treatment continuation were not explored in these studies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Cai¹,

Decuypere²,

Chevalier³

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

Background Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment discontinuation of patients on paliperidone palmitate and risperidone microsphere. Additionally, treatment discontinuation between patients with PP1M and PP3M was compared. Methods The IQVIA Longitudinal Prescription databases were used. Risk factors of treatment discontinuation were identified by a multilevel survival regression using Cox proportional hazards model. Kaplan Meier analyses were performed by identified significant risk factors. Results Twenty-five thousand three hundred sixty-one patients (France: 9,720; Germany: 14,461; Belgium: 1,180) were included. Over a one-year follow-up period, a significant lower treatment discontinuation was observed for patients newly initiated on paliperidone palmitate (53.8%) than those on risperidone microspheres (85.4%). Additionally, a significantly lower treatment discontinuation was found for ‘stable’ PP3M patients (19.2%) than ‘stable’ PP1M patients (37.1%). Patients were more likely to discontinue when drugs were prescribed by GP only (HR = 1.68, p < 0.001 vs. psychiatrist only) or if they were female (HR = 1.07, p < 0.001), whereas discontinuation decreased with age (31–50 years: HR = 0.95, p = 0.006 and > 50 years: HR = 0.91, p < 0.001 vs. 18–30 years). Conclusions This study demonstrates that patients stay significantly longer on treatment when initiated on paliperidone palmitate as compared to risperidone microspheres. It also indicated a higher treatment continuation of PP3M over PP1M. Treatment continuation is likely to be improved by empowering GPs with mental health knowledge and managing patients by a collaborative primary care-mental health model. Further research is needed to understand why females and younger patients have more treatment discontinuation.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Cai¹,

Decuypere²,

Chevalier³

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…In agreement, (OLIVEIRA et al, 2012) also pointed to Haloperidol (oral administration) as the most prescribed drug, followed by intramuscular Haloperidol Decanoate, through a research conducted in a CAPS. It is also worth mentioning that, because it presents prolonged action, Haloperidol Decanoate improves the treatment of patients with schizophrenia, because it maintains plasma levels and avoids re-hospitalizations (GUILLON et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…In this context, it is believed intense use of Haloperidol and its associations are due to its lower cost, about three times lower than the use of a more modern antipsychotic that has fewer undesirable effects (NUNES et al, 2018). In addition, studies have revealed 5% increase in the use of long-acting antipsychotics in Brazil by patients who have not adhered to oral antipsychotics would save approximately R$ 0.3 million every year (GUILLON et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Haldol Decanoato: Aspectos Do Uso Do Fármaco Em Indivíduos No Nordeste Do Brasil

Oliveira,

Silva,

Silva

et al. 2023

Rev. Interfaces

View full text Add to dashboard Cite

Introduction: Haldol Decanoate is a first-generation antipsychotic effective against the positive symptoms of psychosis, namely delusions and hallucinations. In addition, the medication also exerts a sedative action in conditions of psychomotor agitation. Objective: To identify sociodemographic aspects, diagnosis and administration of Haldol Decanoate in patients of a Psychosocial Care Center. Method: This is a documental study, with quantitative design, collected from medical records of users of a Psychosocial Care Center in Northeast Brazil. Data collection was carried out from June to August 2022. 75 medical records were identified, of these, 51 met the criteria of this study and compose the research sample. Results: The medical records of patients using Haldol Decanoate in the referred institution presented with higher prevalence: age between 31 and 40 years, male gender, single marital status, base diagnosis Schizophrenia and with dose interval of Haldol Decanoate of 15 days, making use of 1 ampoule. Conclusion: The identification of the users' profile and the characteristics inherent to the outpatient use of Haldol Decanoate are important for the improvement, implementation and prioritization of strategic actions for health professionals, managers and public policy makers, influencing an efficient mental health care.

show abstract

Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study

et al. 2020

View full text Add to dashboard Cite

Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: A retrospective observational study in France

Cited by 4 publications

References 0 publications

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Haldol Decanoato: Aspectos Do Uso Do Fármaco Em Indivíduos No Nordeste Do Brasil

Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study

Contact Info

Product

Resources

About